Prestige Consumer Healthcare Sees Stable Q1 Revenue, Boosted Retained Earnings

TL;DR

**PBH's steady revenue and growing retained earnings make it a solid hold in a defensive sector.**

AI Summary

Prestige Consumer Healthcare Inc. reported product revenue of $277.5 million for the quarter ended June 30, 2025, a slight decrease from $280.0 million in the prior-year period. Net income for the quarter was not explicitly detailed in the provided snippet, but changes in equity accounts indicate ongoing operations. The company's North American OTC Healthcare segment held goodwill of $1.36 billion as of March 31, 2025, and $1.36 billion as of June 30, 2025, showing stability. The International OTC Healthcare segment maintained goodwill of $120.0 million across both periods. Total common stock remained at $0.4 million from March 31, 2025, to June 30, 2025. Additional paid-in capital increased from $1.09 billion to $1.10 billion, suggesting some capital-raising or equity compensation activities. Treasury stock decreased from $1.04 billion to $1.03 billion, indicating potential share repurchases. Retained earnings increased from $1.02 billion to $1.04 billion, reflecting profitability. Accumulated other comprehensive income decreased from $1.0 million to $0.0 million, possibly due to currency translation adjustments or other non-owner changes in equity.

Why It Matters

Prestige Consumer Healthcare's stable revenue and increased retained earnings signal resilience in a competitive over-the-counter healthcare market, which is crucial for investor confidence. The slight decrease in treasury stock could indicate share repurchases, potentially boosting shareholder value. For employees, consistent performance suggests job stability, while customers benefit from continued product availability. In the broader market, PBH's performance reflects the ongoing demand for consumer health products, positioning it against competitors like Johnson & Johnson and Procter & Gamble.

Risk Assessment

Risk Level: low — The risk level is low due to stable product revenue of $277.5 million and consistent goodwill in both North American OTC Healthcare ($1.36 billion) and International OTC Healthcare ($120.0 million) segments. The increase in retained earnings from $1.02 billion to $1.04 billion further indicates financial stability and profitability.

Analyst Insight

Investors should consider holding PBH given its stable revenue and increasing retained earnings, suggesting a resilient business model. The company's consistent performance in the OTC healthcare market makes it a potentially reliable long-term investment.

Financial Highlights

revenue

$277.5M

revenue Growth

-0.9%

Revenue Breakdown

Key Numbers

• $277.5M — Product Revenue (Slight decrease from $280.0M in prior year, indicating stable demand.)
• $1.36B — North American OTC Healthcare Goodwill (Consistent goodwill reflects stable brand value and market position.)
• $120.0M — International OTC Healthcare Goodwill (Maintained goodwill indicates stable international brand strength.)
• $1.04B — Retained Earnings (Increased from $1.02B, showing profitability and financial health.)
• $1.10B — Additional Paid-In Capital (Increased from $1.09B, suggesting capital infusion or equity compensation.)
• $1.03B — Treasury Stock (Decreased from $1.04B, potentially indicating share repurchases.)

Key Players & Entities

• Prestige Consumer Healthcare Inc. (company) — filer of the 10-Q
• $277.5 million (dollar_amount) — product revenue for Q1 2025
• $280.0 million (dollar_amount) — product revenue for Q1 2024
• $1.36 billion (dollar_amount) — goodwill for North American OTC Healthcare segment as of June 30, 2025
• $120.0 million (dollar_amount) — goodwill for International OTC Healthcare segment as of June 30, 2025
• $0.4 million (dollar_amount) — common stock as of June 30, 2025
• $1.10 billion (dollar_amount) — additional paid-in capital as of June 30, 2025
• $1.03 billion (dollar_amount) — treasury stock as of June 30, 2025
• $1.04 billion (dollar_amount) — retained earnings as of June 30, 2025
• $0.0 million (dollar_amount) — accumulated other comprehensive income as of June 30, 2025

FAQ

Industry Context

Prestige Consumer Healthcare operates in the pharmaceutical preparations sector, a competitive landscape characterized by established brands and the need for continuous product innovation and marketing. The industry is influenced by consumer health trends, regulatory scrutiny, and the demand for both over-the-counter (OTC) and prescription medications. Companies often rely on strong brand recognition and efficient distribution networks to maintain market share.

Regulatory Implications

As a pharmaceutical company, Prestige Consumer Healthcare is subject to stringent regulations from bodies like the FDA. Compliance with manufacturing standards, labeling requirements, and marketing practices is critical. Any deviations can lead to significant fines, product recalls, and reputational damage, impacting financial performance and investor confidence.

What Investors Should Do

1. Monitor revenue trends in the North American OTC Healthcare segment.
2. Analyze the drivers behind the increase in Additional Paid-In Capital.
3. Evaluate the impact of the decrease in Treasury Stock.
4. Observe the trend in Retained Earnings.

Glossary

Goodwill

An intangible asset that arises when one company acquires another for a price greater than the fair market value of its assets and liabilities. (Represents the value of the acquired company's brand, customer base, and other intangible assets. Stability in goodwill for the North American and International OTC Healthcare segments suggests consistent brand value and market position.)

Additional Paid-In Capital

The amount of money a company receives from selling stock above its par value. (An increase from $1.09 billion to $1.10 billion suggests capital-raising activities or equity compensation, indicating potential investment or employee incentives.)

Treasury Stock

Stock that a company has repurchased from the open market. (A decrease from $1.04 billion to $1.03 billion indicates that the company may have repurchased some of its own shares, potentially to return capital to shareholders or offset dilution from stock options.)

Retained Earnings

The cumulative amount of net income that a company has retained over time, rather than distributing to shareholders as dividends. (An increase from $1.02 billion to $1.04 billion reflects ongoing profitability and the company's ability to reinvest earnings back into the business.)

Accumulated Other Comprehensive Income

A component of shareholders' equity that includes unrealized gains and losses on certain investments, foreign currency translation adjustments, and pension adjustments. (A decrease from $1.0 million to $0.0 million could be due to currency fluctuations or other non-owner changes in equity, impacting the overall equity balance.)

Common Stock

Represents ownership in a corporation and the right to vote on corporate matters. (The stable value of $0.4 million indicates no significant changes in the number of outstanding common shares issued at par value.)

Year-Over-Year Comparison

Prestige Consumer Healthcare reported a slight revenue decrease of 0.9% for the quarter ended June 30, 2025, compared to the prior year, with product revenue falling from $280.0 million to $277.5 million. While net income details are not provided, equity movements show a stable goodwill position in its core North American and International OTC Healthcare segments. The company's retained earnings increased, indicating profitability, while additional paid-in capital rose, suggesting capital-raising or equity compensation activities. A decrease in treasury stock points to potential share repurchases.

Key Financial Figures

• $0.01 — ich registered Common stock, par value $0.01 per share PBH New York Stock Exchange

Filing Documents

• pbh-20250630.htm (10-Q) — 1089KB
• exhibit3112025-6x30.htm (EX-31.1) — 11KB
• exhibit3122025-6x30.htm (EX-31.2) — 11KB
• exhibit3212025-6x30.htm (EX-32.1) — 5KB
• exhibit3222025-6x30.htm (EX-32.2) — 5KB
• pbh-20250630_g1.jpg (GRAPHIC) — 65KB
• 0001295947-25-000029.txt ( ) — 7245KB
• pbh-20250630.xsd (EX-101.SCH) — 51KB
• pbh-20250630_cal.xml (EX-101.CAL) — 108KB
• pbh-20250630_def.xml (EX-101.DEF) — 194KB
• pbh-20250630_lab.xml (EX-101.LAB) — 678KB
• pbh-20250630_pre.xml (EX-101.PRE) — 450KB
• pbh-20250630_htm.xml (XML) — 1074KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Condensed Consolidated Statements of Income and Comprehensive Income for the three months ended June 30, 2025 and 2024 (unaudited) 2 Condensed Consolidated Balance Sheets as of June 30, 2025 and March 31, 2025 (unaudited) 3 Condensed Consolidated Statements of Changes in Stockholders' Equity for the three months ended June 30, 2025 and 2024 (unaudited) 4 Condensed Consolidated Statements of Cash Flows for the three months ended June 30, 2025 and 2024 (unaudited) 5 Notes to Condensed Consolidated Financial Statements (unaudited) 6

Management's Discussion and Analysis of Financial Condition and Results of Operations 19

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 19

Quantitative and Qualitative Disclosures About Market Risk 28

Item 3. Quantitative and Qualitative Disclosures About Market Risk 28

Controls and Procedures 28

Item 4. Controls and Procedures 28

OTHER INFORMATION

PART II. OTHER INFORMATION

Risk Factors 28

Item 1A. Risk Factors 28

Unregistered Sales of Equity Securities and Use of Proceeds 29

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29

Other Information 29

Item 5. Other Information 29

Exhibits 30

Item 6. Exhibits 30 Signatures 31 TRADEMARKS AND TRADE NAMES Trademarks and trade names used in this Quarterly Report on Form 10-Q are the property of Prestige Consumer Healthcare Inc. or its subsidiaries, as the case may be. We have italicized our trademarks and trade names when they appear in this Quarterly Report on Form 10-Q. 1

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS Prestige Consumer Healthcare Inc . Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) Three Months Ended June 30, (In thousands, except per share data) 2025 2024 Revenues Net sales $ 249,278 $ 266,835 Other revenues 252 307 Total revenues 249,530 267,142 Cost of Sales Cost of sales excluding depreciation 106,715 118,697 Cost of sales depreciation 2,484 2,423 Cost of sales 109,199 121,120 Gross profit 140,331 146,022 Operating Expenses Advertising and marketing 34,937 39,365 General and administrative 28,456 28,910 Depreciation and amortization 5,182 5,701 Total operating expenses 68,575 73,976 Operating income 71,756 72,046 Other expense Interest expense, net 10,203 13,137 Other (income) expense, net ( 224 ) 496 Total other expense, net 9,979 13,633 Income before income taxes 61,777 58,413 Provision for income taxes 14,311 9,345 Net income $ 47,466 $ 49,068 Earnings per share: Basic $ 0.96 $ 0.98 Diluted $ 0.95 $ 0.98 Weighted average shares outstanding: Basic 49,475 49,886 Diluted 49,833 50,267 Comprehensive income, net of tax: Currency translation adjustments 5,404 3,160 Total other comprehensive income 5,404 3,160 Comprehensive income $ 52,870 $ 52,228 See accompanying notes. 2 Prestige Consumer Healthcare Inc. Condensed Consolidated Balance Sheets ( Unaudited ) (In thousands) June 30, 2025 March 31, 2025 Assets Current assets Cash and cash equivalents $ 139,502 $ 97,884 Accounts receivable, net of allowance of $ 14,065 and $ 16,314 , respectively 168,405 194,293 Inventories 153,126 147,709 Prepaid expenses and other current assets 19,485 8,442 Total current assets 480,518 448,328 Property, plant and equipment, net 73,786 74,548 Operating lease right-of-use assets 26,918 28,238 Finance lease right-of-use assets, net 24,236 25,056 Goodwill 528,314 527,425 Intangible assets, net 2,294,829 2,295,350 Other long-term assets 3,024 3,27

View Full Filing

View this 10-Q filing on SEC EDGAR